Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Nirsevimab
This webpage features the drug dictionary entry for nirsevimab, providing the National Cancer Institute's definition. It describes nirsevimab as a special type of medicine called …
Ask aRCie
ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 Months of Age at Increased Risk of Severe Disease Entering Their Second RSV Season
This webpage provides evidence for the recommendations made by the Advisory Committee on Immunization Practices (ACIP) for the use of nirsevimab for a population of …
The Respiratory Syncytial Virus Vaccine and Monoclonal Antibody Landscape: The Road to Global Access
2024
· University Medical Center Utrecht,
· Yenepoya University,
· University of Edinburgh,
· National Institutes of Health (NIH),
· London School of Hygiene and Tropical Medicine,
· London School of Hygiene & Tropical Medicine
This article is about the fight against respiratory syncytial virus (RSV), a major cause of illness in infants and older adults. It describes new vaccines …
Beyfortus-nirsevimab injection (Drug Label Information)
2024
· National Library of Medicine
This webpage provides drug label information for the Beyfortus- nirsevimab injection. It describes the drug's dosage, forms, and strengths. Beyfortus is given as an injection …
Nirsevimab (Beyfortus) Product & Ordering Information
This webpage provides information about nirsevimab (Beyfortus), describing the different doses available, how to order and store it, and its cost. Practices need to forecast …
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
2024
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service,
· University of Rochester,
· University of Cincinnati,
· Cincinnati Children's Hospital Medical Center,
· Vanderbilt University,
· Texas Children's Hospital,
· Baylor College of Medicine,
· University of Washington,
· University of Pittsburgh,
· Children's Mercy Kansas City
This study looks at the impact of respiratory syncytial virus (RSV) in young children during the 2023-2024 season. It describes how two new RSV prevention …
Universal Infant Immunisation Against Respiratory Syncytial Virus and European Inequalities: The Pandemics Lesson Has Not Been Learnt
2023
· Hôpital Antoine-Béclère AP-HP,
· Université Paris-Saclay,
· American College of Emergency Physicians,
· Hospital General Universitario Gregorio Marañón,
· St. Marien Children's Hospital,
· University Medical Centre Utrecht,
· Respiratory Syncytial Virus NETwork (ReSViNET) Foundation,
· University Hospital of Padova
This comment discusses the challenges of implementing universal infant immunization against respiratory syncytial virus (RSV) in Europe. RSV is a major cause of illness in …
Potential Effects on Elderly People From Nirsevimab Use in Infants
2024
· World Health Organization (WHO),
· Instituto de Estudios de Ciencias de la Salud de Castilla y León, ICSCYL,
· Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC),
· University of Valladolid
This article is about nirsevimab, a new treatment for infants to prevent severe RSV disease. It describes how using nirsevimab in babies might help protect …
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
This article describes the use of nirsevimab, a new drug approved in 2023, to prevent severe respiratory syncytial virus (RSV) disease in infants and young …
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
2024
· Centers for Disease Control and Prevention (CDC),
· Vanderbilt University,
· Seattle Children's Hospital,
· Baylor College of Medicine,
· University of Rochester
This study examines the effectiveness of nirsevimab, a monoclonal antibody, in preventing RSV-related hospitalizations in infants during their first RSV season. Conducted from October 2023 …